Results 181 to 190 of about 60,399 (263)

Single‐cell analysis reveals neuroprotective histone deacetylase inhibitor pathways

open access: yesAlzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) involves β‐amyloid (Aβ) accumulation, tau pathology, and neuroinflammation, driving cognitive decline. Despite extensive research, disease‐modifying therapies remain elusive. We integrated single‐cell RNA sequencing (scRNA‐seq), spatial transcriptomics, and in vitro validation to identify repurposable ...
Madeline Peyton   +12 more
wiley   +1 more source

The BRAF-specific region suppresses cysteine-rich domain-lipid interaction independently of canonical autoinhibition by the 14-3-3 dimer. [PDF]

open access: yesProtein Sci
Revazishvili V   +8 more
europepmc   +1 more source

Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials

open access: yesFood Science &Nutrition, Volume 14, Issue 2, February 2026.
Curcuminoids remain one of the most studied dietary polyphenols as a cancer prevention and treatment agent. Inflammation and tumor progression are related to the NF‐κB signaling pathway, which is also suppressed by curcuminoids. Curcuminoids prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF‐kB pathways ...
Ushna Momal   +14 more
wiley   +1 more source

Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers

open access: yesMedComm, Volume 7, Issue 2, February 2026.
The BRAF25 meta‐signature effectively captures BRAF‐driven oncogenic activity. By enabling precise patient stratification with distinct mutation profiles, BRAF25 identifies BRAF‐active tumor subtypes and provides superior prognostic value compared with mutation status alone.
Kaidi Yang   +7 more
wiley   +1 more source

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compared with dual blockade with trastuzumab and pertuzumab (TP), but was associated with greater grade ≥ 3 toxicity, particularly diarrhea.
Jiahui Huang   +17 more
wiley   +1 more source

Host Oxidative Response Capacity Determines Longevity Outcomes of Microbial Interventions

open access: yesAging Cell, Volume 25, Issue 2, February 2026.
Genetic variation determines whether microbial interactions extend or shorten host lifespan via redox homeostasis. This discovery highlights the critical role of host genetics in shaping microbiota‐driven aging, offering a new framework for precision microbiome interventions tailored to individual needs for promoting longevity.
Xusheng Hao   +8 more
wiley   +1 more source

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. [PDF]

open access: yesOncotarget, 2017
Buschow SI   +21 more
europepmc   +1 more source

Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway

open access: yesCancer Science, Volume 117, Issue 2, Page 364-376, February 2026.
BACH1 is associated with poor prognosis in BC patients and plays a critical role in promoting tumor progression and metastasis. Furthermore, we elucidated the mechanism by which BACH1 facilitates tumor progression and metastasis, primarily through activation of the EMT pathway. These findings suggest that BACH1 may serve as a novel prognostic biomarker
Tomoya Hatayama   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy